Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

76.88USD
21 Feb 2017
Change (% chg)

$-0.32 (-0.41%)
Prev Close
$77.20
Open
$76.53
Day's High
$77.02
Day's Low
$76.48
Volume
3,037,413
Avg. Vol
3,488,573
52-wk High
$83.58
52-wk Low
$66.93

Latest Key Developments (Source: Significant Developments)

Incyte reports Q4 earnings per share $0.05
Tuesday, 14 Feb 2017 07:00am EST 

Incyte Corp : Incyte reports 2016 fourth-quarter and year-end financial results, provides 2017 financial guidance and updates on key clinical programs . Q4 revenue $326 million versus I/B/E/S view $324.4 million . Q4 earnings per share $0.05 . Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees 2017 Jakafi net product revenues $1,020-$1,070 million . Sees 2017 ongoing research and development expenses $785-$835 million . Sees 2017 change in fair value of acquisition-related contingent consideration $30-$35 million . Incyte Corp - pivotal program of ruxolitinib as a treatment for patients with essential thrombocythemia is also expected to begin in 2017 .Incyte - phase 3 trials in steroid-refractory acute, steroid-refractory chronic gvhd, respectively, expected to begin in 2017 with novartis.  Full Article

Novartis says Alcon launches new lens for astigmatism
Thursday, 26 Jan 2017 01:00am EST 

Novartis : Says Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery Further company coverage: [NOVN.S] (Reporting By Zurich newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

Novartis expects CART therapy CTL019 to exceed $1 bln in annual sales
Wednesday, 25 Jan 2017 08:50am EST 

Novartis : Says elevates cart therapy ctl019 to group of drugs it expects will be blockbusters, with at least $1 billion in annual sales . Says diffuse large b-cell lymphoma indication likely to propel ctl019 to blockbuster status, filing expected in 2017 depending on data .still plans initial q2 2017 regulatory filing in United States for CTL019 in in relapsed/refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia.  Full Article

Novartis's Alcon head expects op. profit to hit trough in 2017
Wednesday, 25 Jan 2017 08:36am EST 

Novartis Ag : Alcon unit head says fixing supply, service issues 'more challenging than originally imagined' . Ceo says has not ruled out sale of alcon to strategic buyer .Alcon head expects operating profit to reach trough in 2017.  Full Article

Novartis CEO plans to meet with US President Trump, no date set
Wednesday, 25 Jan 2017 07:06am EST 

Novartis Ag : Says expects to grow in each year in 2018, 2019 and 2020 . Cfo says plans to finance $5 billion share buyback with debt . Ceo says goodwill, intangibles of alcon is $16.9 billion, does not anticipate loss after impairment testing . Ceo won't speculate on prequisites for keeping alcon, 'we're going to make a decision" based on how alcon progresses . Ceo says has outcomes based pricing contracts for gilenya, tasigna following entresto deals .Ceo says plans to meet with president trump, "love to in coming months sit down with administration" to consult on affordable care; no meeting set yet.  Full Article

Alcon receives U.S. FDA approval for acrysof® iq restor® +3.0d multifocal toric intraocular lens
Thursday, 22 Dec 2016 06:00pm EST 

Novartis Ag : Alcon - U.S. commercialization expected to start on a rolling basis in Q1 of 2017 for acrysof iq restor .Alcon receives U.S. FDA approval for acrysof® iq restor® +3.0d multifocal toric intraocular lens for cataract patients.  Full Article

Sun Pharma to buy Novartis' cancer drug Odomzo
Wednesday, 21 Dec 2016 10:01pm EST 

Sun Pharmaceutical Industries Ltd : Says Sun Pharma to acquire branded oncology product Odomzo for global markets . Says acquisition of Odomzo from Novartis . Says greement has been signed for an upfront payment of US$ 175 million and additional milestone payments. .says Odomzo is used for treatment of adult patients with labcc that has recurred following surgery or radiation therapy.  Full Article

Novartis signs licensing deal with Sunovion Pharma
Wednesday, 21 Dec 2016 08:00am EST 

Novartis Ag :Novartis - signed licensing deal with Sunovion Pharma for US commercial rights to its three treatments for chronic obstructive pulmonary disease.  Full Article

Novartis says LEE011 (ribociclib) granted FDA priority review
Tuesday, 1 Nov 2016 07:30am EDT 

Novartis Pharmaceuticals Corp:Novartis LEE011 (ribociclib) granted FDA priority review for first-line treatment of HR+/HER2- advanced breast cancer.  Full Article

Novartis Bioventures reports 11.8 pct passive stake in Ra Pharmaceuticals - SEC filing
Monday, 31 Oct 2016 04:51pm EDT 

Novartis Ag :Novartis Bioventures Ltd reports 11.8 percent passive stake in Ra Pharmaceuticals Inc as of Oct. 31 - SEC filing.  Full Article

More From Around the Web

Merck stopping late stage study as another Alzheimer's drug fails

Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.